登录 注册 会员服务 联系我们

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

  • Published:2015-07-21 Issue:1 Volume:142 Page:157-165
  • ISSN:0171-5216
  • Container-title:Journal of Cancer Research and Clinical Oncology
  • language:en
  • Short-container-title:J Cancer Res Clin Oncol

Author:

Kim Ji-Won,Kim Debora K.,Min Ahrum,Lee Kyung-Hun,Nam Hyun-Jin,Kim Jee Hyun,Kim Jin-Soo,Kim Tae-Yong,Im Seock-Ah,Park In Ae

Funder

Seoul National University Hospital Research Fund

Basic Science Research Program

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Reference32 articles.

1. Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32(33):3753–3761. doi: 10.1200/JCO.2013.54.5384

2. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108(9):1807–1809. doi: 10.1038/bjc.2013.164

3. Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, Weidler JM, Huang W, Winslow J, Jankowski T, Czartoryska-Arlukowicz B, Wysocki PJ, Foszczynska-Kloda M, Radecka B, Litwiniuk MM, Zok J, Wisniewski M, Zuziak D, Biernat W, Jassem J (2014) Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin Cancer Res 20(10):2805–2813. doi: 10.1158/1078-0432.CCR-13-2782

4. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. doi: 10.1056/NEJMoa064320

5. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL (2011) Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71(5):1871–1882. doi: 10.1158/0008-5472.CAN-10-1872
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3